LOX has been identified as an important regulator of the hypoxia-induced tumor progression pathway through a HIF-1α-dependent mechanism in numerous cancer types, such as breast, head and neck, prostate and renal cell carcinomas [15,16,17]. Here, LOX is linked to neoplasm.